Conduit Pharmaceuticals Stock Cash Flow From Operations
| CDT Stock | 0.09 0 4.47% |
Conduit Pharmaceuticals fundamentals help investors to digest information that contributes to Conduit Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Conduit Stock. The fundamental analysis module provides a way to measure Conduit Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Conduit Pharmaceuticals stock.
Conduit |
Conduit Pharmaceuticals Company Cash Flow From Operations Analysis
Conduit Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Conduit Pharmaceuticals Cash Flow From Operations | (7.72 M) |
Most of Conduit Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Conduit Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Conduit Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Conduit Pharmaceuticals is extremely important. It helps to project a fair market value of Conduit Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Conduit Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Conduit Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Conduit Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Conduit Pharmaceuticals has (7.72 Million) in Cash Flow From Operations. This is 101.47% lower than that of the Life Sciences Tools & Services sector and 112.36% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.8% higher than that of the company.
Conduit Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Conduit Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Conduit Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Conduit Pharmaceuticals by comparing valuation metrics of similar companies.Conduit Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Conduit Fundamentals
| Return On Asset | -3.22 | ||||
| Current Valuation | 13.39 M | ||||
| Shares Outstanding | 116.8 M | ||||
| Shares Owned By Insiders | 49.11 % | ||||
| Shares Owned By Institutions | 4.05 % | ||||
| Number Of Shares Shorted | 2.36 M | ||||
| EBITDA | (324 K) | ||||
| Net Income | (535 K) | ||||
| Total Debt | 985 K | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (7.72 M) | ||||
| Short Ratio | 0.14 X | ||||
| Earnings Per Share | (0.23) X | ||||
| Beta | 2.12 | ||||
| Market Capitalization | 10.55 M | ||||
| Total Asset | 7.22 M | ||||
| Retained Earnings | (11.3 M) | ||||
| Working Capital | 3.93 M | ||||
| Net Asset | 7.22 M |
About Conduit Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Conduit Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Conduit Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Conduit Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.